Investor082,
First of all it’s possible to likely that not every big pharma is a welcome partner. Seems to me that Merck was vetted since Dr. Duffy was brought in to help but what about the rest? Mr. Cofer Black is on the board for a good reason and if you have not figured out by now that NWBO can be considered a threat to future big pharma profits then shared due diligence to this point by many longs has just been ignored by you. I believe you make too many assumptions about partnership timing although I agree with you that a partnership deal might be announced after a MHRA approval just because the need to do so can’t be kept secret forever. Partnerships now are not likely going to be inked on terms that big pharma wants. Anykne thinking so should have figured this out by now. Big pharma waited too long to get real and now they are just holding on to what they have for as long as possible before deals are made. Deals will be made because of THEIR NEED to stay relevant in light of possible threats from generic competition not only directly but also for combo scenarios with L before Direct takes center stage. These threats will be coming right when Flaskworks is powering up. See the issue big pharma reliance on checkpoint inhibitor profits has created as the patent cliff approaches and their attempts to move to a new patent protected administration method has created a greater risk of death. NWBO does and that puts them in the driver’s seat with negotiations. So will big pharma bite the bullet at approval or wait until Flaskworks to try and maximize current advantage as long as possible before funding for Direct trials becomes available? Some of the bears here want to project that the price won’t rise very much with approval. Gee, I wonder why; ). Best wishes.
Market Data 
Markets 
AI
